Approval of teplizumab: implications for patients

Nat Rev Endocrinol. 2023 Jul;19(7):377-378. doi: 10.1038/s41574-023-00849-w.

Authors

Cate Speake¹, Carla J Greenbaum²

Affiliations

¹ Center for Interventional Immunology and Diabetes Program, Benaroya Research Institute, Seattle, WA, USA.
² Center for Interventional Immunology and Diabetes Program, Benaroya Research Institute, Seattle, WA, USA. cjgreen@benaroyaresearch.org.

PMID: 37202589
DOI: 10.1038/s41574-023-00849-w

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Diabetes Mellitus, Type 1*
Humans
Hypoglycemic Agents

Substances

teplizumab
Antibodies, Monoclonal, Humanized
Hypoglycemic Agents